Alpha-Synuclein Aggregation Pathway
Overview
[Alpha-synuclein](/proteins/alpha-synuclein) aggregation represents one of the central pathological hallmarks of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and related synucleinopathies. The pathological accumulation of misfolded alpha-synuclein protein into Lewy bodies and Lewy neurites characterizes the majority of PD cases and provides a mechanistic link between genetic risk factors and sporadic disease[@spillantini1997]. Understanding the pathways governing alpha-synuclein homeostasis, misfolding, aggregation, and propagation is essential for developing disease-modifying therapies targeting the proteinopathic basis of these neurodegenerative disorders.
The alpha-synuclein protein is encoded by the [SNCA](/genes/snca) gene and is abundant in the brain, particularly in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release. Under physiological conditions, alpha-synuclein exists as a natively unfolded monomer that can adopt alpha-helical conformations upon membrane binding. However, various genetic, environmental, and age-related factors can trigger the protein's misfolding into beta-sheet rich oligomers and fibrils that serve as the building blocks of Lewy pathology[@goedert2017].
The progression of alpha-synuclein pathology follows a predictable pattern in PD, beginning in the lower brainstem and olfactory bulb, advancing to the midbrain (including the substantia nigra), and eventually affecting cortical regions[@braak2003]. This staging system has been validated in multiple cohorts and provides a framework for understanding disease progression.
Molecular Biology of Alpha-Synuclein
Protein Structure and Function
Alpha-synuclein is a 140-amino acid protein encoded by the [SNCA](/genes/snca) gene located on chromosome 4q21. The protein comprises three distinct domains[@fink1996]:
N-terminal region (1-60): Contains seven imperfect repeats of the sequence KTKEGV that mediate lipid binding and form alpha-helical structures upon association with membranes. This region also contains the sites of familial PD mutations (A30P, A53T, E46K, G51D, H50Q).
Central hydrophobic region (61-95): Known as the non-[amyloid-beta](/proteins/amyloid-beta) component (NAC) domain, this region is highly prone to aggregation and is essential for fibril formation. The NAC domain contains residues critical for beta-sheet formation.
C-terminal region (96-140): Acidic and proline-rich, this domain is intrinsically disordered and may serve as a chaperone-like regulatory domain. The C-terminal tail also contains sites for phosphorylation (Ser129) and other post-translational modifications.Under normal conditions, alpha-synuclein participates in synaptic vesicle pool management, dopamine transmission regulation, and neuronal plasticity. The protein shuttles between cytosolic and membrane-associated pools, with its membrane binding being regulated by post-translational modifications and cellular signaling events[@jensen2019].
Physiological Functions
Beyond its pathological aggregation, alpha-synuclein has important physiological roles:
- Regulation of synaptic vesicle trafficking and clustering
- Modulation of dopamine synthesis and release
- Presynaptic plasticity and long-term potentiation
- Calcium homeostasis
- Lipid metabolism
Transgenic mice lacking alpha-synuclein show relatively mild phenotypes, suggesting functional redundancy, while overexpression leads to neurodegeneration, highlighting the importance of proper regulation.
Post-Translational Modifications
Alpha-synuclein undergoes numerous post-translational modifications that influence its aggregation propensity[@mak2020]:
- Phosphorylation: Phosphorylation at Ser129 is the predominant modification in Lewy bodies, with approximately 90% of pathological alpha-synuclein being phosphorylated at this site. Kinases including G-protein-coupled receptor kinases (GRKs) and casein kinases contribute to this modification. Ser129 phosphorylation promotes fibril formation and may be a therapeutic target.
- Ubiquitination: Polyubiquitination targets alpha-synuclein for proteasomal degradation, though Lewy body alpha-synuclein is often conjugated to ubiquitin chains that may be atypical (e.g., Lys63-linked). Ubiquitination may be a marker of cellular stress rather than a degradation signal.
- Truncation: C-terminal truncations enhance aggregation propensity and are found in pathological inclusions. Truncated alpha-synuclein (e.g., 1-120) serves as an efficient seed for aggregation of full-length protein.
- Oxidation and nitration: Reactive oxygen and nitrogen species can modify tyrosine residues (Y125, Y133, Y136), promoting aggregation. Oxidized alpha-synuclein shows enhanced oligomerization and neurotoxicity.
- SUMOylation: SUMOylation at Lys102 and Lys96 modulates aggregation, with SUMOylated alpha-synuclein showing reduced fibrillization.
Mechanisms of Aggregation
Nucleation and Oligomerization
The aggregation of alpha-synuclein follows a nucleation-dependent polymerization model[@schmitt2022]:
Lag phase: Monomeric alpha-synuclein undergoes conformational changes to form transient oligomeric nuclei. This phase can be accelerated by pre-existing seeds ("seeded" aggregation).
Growth phase: Addition of monomers to existing nuclei leads to rapid fibril elongation. The fibrils grow through a "dock-lock" mechanism involving conformational conversion of monomers.
Plateau phase: Equilibrium between monomers, oligomers, and fibrils is reached.The toxic oligomeric species formed during aggregation are increasingly recognized as the primary neurotoxic entities, rather than the mature fibrils themselves[@hafner2019]. These oligomers can be:
- Membrane-permeabilizing: Forming pores that disrupt cellular ion homeostasis
- Synaptic disruptors: Impairing neurotransmitter release and reuptake
- Mitochondrially toxic: Targeting and damaging mitochondrial function
- Prion-like: Capable of seeding further aggregation in a templated manner[@ullah2018]
Oligomer Types and Toxicity
Alpha-synuclein oligomers exist in multiple forms:
- Protofibrils: Early oligomeric intermediates that can be circular or chain-like
- Annular oligomers: Pore-like structures that disrupt membranes
- Spherical oligomers: Diffuse aggregates with varying toxicity
- Fibrillar intermediates: On-pathway species that mature into fibrils
The specific oligomer species that are most toxic remains an active area of investigation, but evidence suggests that transient, intermediate oligomers may be particularly pathogenic.
Cellular Quality Control Systems
Multiple cellular pathways attempt to prevent alpha-synuclein aggregation:
| Pathway | Mechanism | Role in PD |
|---------|-----------|------------|
| Ubiquitin-Proasome System (UPS) | Degrades modified alpha-synuclein | Impaired in PD, contributes to accumulation |
| [Autophagy](/entities/autophagy) Pathway (ALP) | Macroautophagy and CMA clear aggregates | Genetic PD risk factors impair ALP function |
| Molecular Chaperones | Hsp70, Hsp40 prevent misfolding | Therapeutic target for enhancement |
| Mitochondrial Quality Control | Mitophagy removes damaged mitochondria | Impaired in PD models |
Prion-Like Propagation
Cell-to-Cell Transmission
A landmark discovery in neurodegeneration research was the recognition that alpha-synuclein pathology can propagate between [neurons](/entities/neurons) in a prion-like manner[@ullah2018]. This process involves:
Release: Alpha-synuclein is released from neurons via exocytosis, exosome secretion, and possibly direct membrane transfer. Release is enhanced by neuronal activity and cellular stress.
Uptake: Recipient cells internalize extracellular alpha-synuclein via various endocytic pathways, including receptor-mediated endocytosis, direct membrane translocation, and phagocytosis.
Seeding: Exogenous alpha-synuclein serves as a template for seeded aggregation of endogenous protein. The conformation of the seed dictates the structure of the resulting aggregates ("strain" concept).
Spread: The process repeats, propagating pathology throughout connected brain regions.This prion-like propagation provides a mechanistic explanation for the staging of Lewy pathology in the brains of PD patients, which follows a predictable pattern beginning in the lower brainstem and advancing to the midbrain and eventually cortical regions[@braak2003].
Evidence for Prion-Like Spread
Multiple lines of evidence support prion-like propagation:
- Lewy bodies can be detected in grafted neurons years after transplantation into PD brains
- Animal models show that injected alpha-synuclein seeds endogenous pathology
- In vitro experiments demonstrate templated conversion of monomeric alpha-synuclein
- Brain-bank studies show progression patterns consistent with spread
Strains and Polymorphisms
Emerging evidence suggests that alpha-synuclein aggregates can adopt distinct conformational "strains" with different biological properties, potentially explaining the clinical heterogeneity of synucleinopathies. These strains may differ in:
- Fibril morphology (as seen by cryo-EM)
- Seeding potency
- Cellular tropism
- Pathogenicity
Strains may also influence the clinical phenotype, with certain conformations associated with PD vs. DLB vs. MSA.
Genetic Factors
SNCA Mutations and Multiplications
Point mutations in [SNCA](/genes/snca) (A53T, A30P, E46K, H50Q, G51D) and genomic multiplications cause familial PD, demonstrating that dysregulated alpha-synuclein expression is sufficient to cause neurodegeneration[@polymeropoulos1997][@zarranz2004]:
- A53T: Found in the Italian Contursi kindred and several other families, promotes rapid aggregation in cellular and animal models. Leads to early-onset PD (median age 46 years).
- A30P: Identified in a German family, reduces membrane binding while promoting aggregation. Associated with variable onset and progression.
- E46K: Found in Spanish families, enhances aggregation and affects sleep behavior. Recapitulates Lewy body pathology in mice.
- G51D: Rare mutation found in a Japanese family, has complex effects on aggregation and cellular trafficking.
- H50Q: Recently identified mutation with intermediate effects on aggregation.
- SNCA duplication/triplication: First identified in the Iowa kindred, causes LOADs (late-onset autosomal dominant) form of PD[@singleton2003]. Gene dosage correlates with age of onset, supporting a toxic gain-of-function mechanism.
Risk Variants
Genome-wide association studies (GWAS) have identified common variants at the [SNCA](/genes/snca) locus as significant risk factors for sporadic PD, highlighting the importance of alpha-synuclein biology even in non-familial disease[@krueger2010]. These variants likely influence [SNCA](/genes/snca) expression through regulatory elements in the promoter and intronic regions.
Interactions with Other Proteins
Alpha-Synuclein and Tau
Alpha-synuclein pathology frequently coexists with tau pathology in PD and PD with dementia[@mak2020][@song2019]:
- Synergistic toxic effects: Co-aggregation and cross-seeding
- Common upstream mechanisms (e.g., oxidative stress, mitochondrial dysfunction)
- Shared therapeutic targets
Alpha-Synuclein and Amyloid-Beta
In the presence of amyloid pathology (as in AD), alpha-synuclein aggregation is accelerated:
- Amyloid-beta may act as a seed for alpha-synuclein
- Shared mechanisms of cellular vulnerability
- Implications for PD-AD overlap
Therapeutic Implications
Disease-Modifying Strategies
Targeting alpha-synuclein aggregation represents a promising therapeutic approach[@b2023]:
Immunotherapies: Active and passive immunization approaches targeting alpha-synuclein are in clinical development. Examples include:
- PRX002 (prasinezumab): Anti-alpha-synuclein monoclonal antibody
- BIIB054 (cinmeron): Antibody targeting oligomeric alpha-synuclein
- ACI-35: Liposome-based vaccine targeting phosphorylated Ser129
Small Molecule Inhibitors: Compounds that prevent aggregation or promote clearance include:
- Anle138b: Oligomer modulator in clinical trials
- NPT200-1: Aggregation inhibitor
- SynuClean-D: Dual inhibitor of alpha-synuclein aggregation
Gene Therapy: Viral vector-mediated delivery of genes encoding anti-aggregation proteins or RNA interference targeting [SNCA](/genes/snca) mRNA.
Enhancing Clearance: Strategies to boost autophagy and proteasomal degradation of alpha-synuclein, including:
- mTOR inhibitors (rapamycin)
- Autophagy inducers (carbamazepine, trehalose)
- Gene therapy for chaperone proteins
Targeting Propagation
Emerging strategies target the prion-like spread of alpha-synuclein:
- Inhibitors of exosome release
- Blocking cell-to-cell transmission
- Anti-seed antibodies
Biomarkers
Alpha-Synuclein as Biomarker
Alpha-synuclein in biofluids serves as a PD biomarker:
- CSF alpha-synuclein: Reduced total alpha-synuclein in PD; elevated phosphorylated Ser129
- Blood/plasma alpha-synuclein: Technical challenges but promising
- Skin biopsy: Detection of phosphorylated alpha-synuclein
Seed Amplification Assays
Real-time quaking-induced conversion (RT-QuIC) and PMCA can detect pathological alpha-synuclein with high sensitivity and specificity:
- Detects oligomeric/fibrillar species
- Differentiates PD from controls
- May detect pre-clinical disease
Summary
The alpha-synuclein aggregation pathway represents a central mechanism in Parkinson's disease pathogenesis. The conversion of natively unfolded alpha-synuclein into toxic oligomers and fibrils disrupts multiple cellular processes, including synaptic function, mitochondrial integrity, and proteostasis. The prion-like propagation of pathology provides a framework for understanding disease progression, while the identification of genetic mutations causing familial PD establishes alpha-synuclein dysregulation as a sufficient cause of neurodegeneration. Therapeutic strategies targeting various stages of the aggregation pathway are under active clinical development, offering hope for disease-modifying treatments in Parkinson's disease.
Oligomer Biology and Toxicity
Structural Characterization of Oligomers
Alpha-synuclein oligomers represent a heterogeneous population of prefibrillar species that form during the aggregation process. These oligomers are increasingly recognized as the primary neurotoxic species in Parkinson's disease, rather than the mature fibrils that comprise Lewy bodies. [@lotharius2005]
The structural properties of toxic oligomers include:
Beta-sheet rich conformation: Despite their prefibrillar nature, many oligomers contain beta-sheet secondary structures that distinguish them from natively unfolded monomers
Membrane binding capacity: Oligomers exhibit enhanced binding to neuronal membranes, particularly at synaptic terminals
Dynamic nature: Oligomeric species are transient and can revert to monomers, disaggregate into fibrils, or continue to grow
Surface exposure of hydrophobic regions: The NAC domain becomes more exposed in oligomeric states, enabling membrane interaction and cellular toxicityThe toxic effects of alpha-synuclein oligomers on neurons involve multiple interconnected pathways:
Synaptic dysfunction: Oligomeric alpha-synuclein localizes to presynaptic terminals where it disrupts synaptic vesicle trafficking and recycling. Studies in transgenic mice demonstrate that oligomer accumulation correlates with progressive loss of synaptic proteins and impaired neurotransmitter release. [@masliah2000]
Calcium dysregulation: Oligomers can form calcium-permeable pores in neuronal membranes, leading to dysregulated calcium homeostasis. This calcium influx activates downstream pathways including calpain-mediated proteolysis and mitochondrial permeability transition.
Mitochondrial dysfunction: Alpha-synuclein oligomers directly bind to mitochondrial membranes and impair complex I activity. [@bookout2020] This creates a vicious cycle where mitochondrial dysfunction increases oxidative stress, which in turn promotes further alpha-synuclein aggregation.
Endoplasmic reticulum stress: Oligomer accumulation in the endoplasmic reticulum triggers the unfolded protein response (UPR) and promotes apoptotic signaling through CHOP and caspase activation.
Targeting Oligomers Therapeutically
Given the central role of oligomers in pathogenesis, several therapeutic strategies specifically target these species:
- Oligomer-specific antibodies: Antibodies that selectively recognize oligomeric conformations over monomers or fibrils
- Small molecule modulators: Compounds like anle138b that shift the aggregation pathway away from toxic oligomers toward inert species
- Seeding inhibitors: Molecules that prevent oligomeric seeds from propagating
Fibril Structure and Lewy Body Formation
Atomic Structure of Alpha-Synuclein Fibrils
Cryo-electron microscopy studies have revealed the atomic structure of alpha-synuclein fibrils, demonstrating that they adopt a cross-beta sheet architecture. The fibril core comprises residues 31-100, forming a double phi-loop structure that stabilizes the fibril. [@giasson2002]
Key structural features include:
- Steric zipper: The interface between beta-sheets creates a "steric zipper" motif characteristic of amyloid fibrils
- Residue-specific folding: The NAC region (residues 61-95) forms the fibril core
- Polymorphic strains: Different preparation conditions and cellular environments produce structurally distinct fibril morphologies
Lewy Body Composition and Maturation
Lewy bodies are complex intracellular inclusions comprising fibrillar alpha-synuclein along with numerous other proteins, lipids, and cellular components. Their formation represents a failed attempt at cellular clearance:
Early stage: Hyperphosphorylated alpha-synuclein accumulates at the presynaptic terminal
Intermediate stage: Ubiquitinated oligomers and fibrils aggregate into visible inclusions
Late stage: Mature Lewy bodies contain a dense core surrounded by a halo of radiating filamentsThe presence of numerous proteins in Lewy bodies reflects the broader disruption of cellular proteostasis in Parkinson's disease. [@pokaly2002]
Cellular and Molecular Interactors
Protein Partners in Aggregation
Alpha-synuclein aggregation is modulated by interactions with numerous cellular proteins:
| Protein | Interaction | Effect on Aggregation |
|---------|-------------|----------------------|
| Tau | Co-aggregation in AD/PD | Synergistic toxicity |
| Amyloid-beta | Cross-seeding in AD/PD | Enhanced pathology |
| Hsp70/Hsp40 | Chaperone binding | Inhibition of aggregation |
| 14-3-3 proteins | Phospho-Ser129 binding | May stabilize oligomers |
| Rab proteins | Synaptic vesicle association | Facilitates propagation |
Lipid Interactions and Membrane Effects
The interaction of alpha-synuclein with lipid membranes is a critical aspect of its biology:
- Membrane binding: The N-terminal region binds to negatively charged phospholipids
- Membrane-induced folding: Lipid binding induces alpha-helical conformation
- Membrane disruption: Aggregated species can permeabilize membranes
- Raft association: Localization to lipid rafts may facilitate prion-like spread
Environmental and Lifestyle Factors
Various environmental and lifestyle factors influence alpha-synuclein aggregation:
Neurotoxin exposure: MPTP, rotenone, and other mitochondrial toxins promote alpha-synuclein pathology in experimental models, linking environmental exposures to disease pathogenesis.
Aging: The decline in cellular clearance mechanisms with age creates a permissive environment for protein aggregation. Decreased autophagy, proteasome activity, and chaperone function all contribute. [@voutsinas2010]
Head trauma: Traumatic brain injury is associated with increased PD risk and may accelerate alpha-synuclein pathology through blood-brain barrier disruption and neuroinflammation.
Protective Factors
Several factors may reduce aggregation risk:
- Physical exercise: Promotes autophagy and enhances cellular clearance
- Caffeine: May reduce aggregation through adenosine receptor antagonism
- Anti-inflammatory drugs: Reduce neuroinflammation that promotes aggregation
Neuroinflammation and Glial Interactions
Microglial Activation
Alpha-synuclein pathology activates microglia through multiple mechanisms:
Direct recognition: Microglial TLR2 and TLR4 recognize aggregated alpha-synuclein
Complement activation: Opsonization with complement proteins promotes phagocytosis
Cytokine release: Activated microglia release TNF-alpha, IL-1beta, and IL-6The resulting neuroinflammation creates a feed-forward loop where inflammatory cytokines promote further alpha-synuclein misfolding and release. [@schmitt2022]
Astrocyte Involvement
Astrocytes also participate in the response to alpha-synuclein pathology:
- Uptake and clearance: Astrocytes can internalize extracellular alpha-synuclein
- Inflammatory signaling: Activated astrocytes release pro-inflammatory mediators
- Metabolic support: Astrocytic dysfunction may reduce neuronal metabolic support
Interaction with Other Proteinopathies
Tau Co-Pathology
The co-occurrence of alpha-synuclein and tau pathology is common, particularly in certain clinical variants. The interaction between these two proteins includes:
- Cross-seeding: Tau fibrils can catalyze alpha-synuclein aggregation and vice versa
- Synergistic toxicity: Combined pathology produces greater neuronal loss
- Distinct anatomical patterns: Lewy bodies and neurofibrillary tangles follow different anatomical distributions
Amyloid-beta Interaction
In brains with both AD and PD pathology, amyloid-beta may influence alpha-synuclein aggregation:
- Modulation of aggregation kinetics: Amyloid-beta can accelerate or inhibit alpha-synuclein fibril formation depending on conditions
- Shared pathways: Both proteins involve similar cellular clearance mechanisms (UPS, autophagy) [@cool2013]
Clinical Implications
Diagnostic Biomarkers
Alpha-synuclein aggregation provides potential biomarkers:
- Cerebrospinal fluid: Decreased alpha-synuclein and increased oligomers in PD
- Skin biopsies: Phospho-Ser129 alpha-synuclein in cutaneous nerves
- Blood-based markers: Alpha-synuclein in extracellular vesicles
Disease Progression Markers
The extent of alpha-synuclein pathology correlates with clinical severity:
- Braak staging: Predicts clinical progression based on anatomical spread
- Oligomer levels: Correlate with cognitive impairment in PD
- Lewy body density: Associated with faster disease progression
Autophagy Enhancement Strategies
The autophagy-lysosome pathway (ALP) represents a critical clearance mechanism for alpha-synuclein. Both macroautophagy and chaperone-mediated autophagy (CMA) contribute to intracellular alpha-synuclein turnover. [@chen2019]
Macroautophagy induction: mTOR inhibitors like rapamycin promote autophagy and reduce alpha-synuclein accumulation in cellular and animal models.
CMA activation: Enhancement of CMA can specifically target alpha-synuclein for lysosomal degradation, as the protein contains a CMA recognition motif.
Lysosomal function: Maintaining lysosomal acidity and enzyme activity is essential for effective clearance of alpha-synuclein aggregates. [@xilouri2009]
Mitochondrial Quality Control
Given the intimate relationship between alpha-synuclein and mitochondrial dysfunction, targeting mitochondrial quality control represents a promising approach:
- Complex I protection: Preserving mitochondrial complex I activity reduces oxidative stress and alpha-synuclein aggregation
- Mitophagy induction: Enhancing PINK1/Parkin-mediated mitophagy removes dysfunctional mitochondria
- Antioxidant therapy: Mitochondrial-targeted antioxidants like MitoQ address oxidative damage
These strategies address both the downstream consequences and upstream drivers of alpha-synuclein pathology. [@schapira2013]
Several novel approaches are under investigation:
Seed-specific inhibitors: Molecules that specifically block templated aggregation
Autophagy enhancers: Compounds that boost cellular clearance of alpha-synuclein
RNA-based therapies: ASOs and siRNA targeting SNCA mRNA
Cellular replacement: Strategies to replace lost neurons using stem cellsBiomarker Development
Improving diagnosis and tracking disease progression:
- Strain-specific detection: Distinguishing different alpha-synuclein conformations
- Real-time monitoring: PET ligands for alpha-synuclein pathology
- Multimodal markers: Combining alpha-synuclein with other biomarkers
α-Synuclein Aggregation Pathway
Mermaid diagram (expand to render)
See Also
- [Alpha-synuclein](/proteins/alpha-synuclein)
- [SNCA](/genes/snca)
- [Parkinson's disease](/diseases/parkinsons-disease)
- [Lewy body dementia](/diseases/dementia-with-lewy-bodies)
- [Mitochondrial dysfunction in PD](/mechanisms/mitochondrial-dysfunction-pd)
- [Autophagy in neurodegeneration](/entities/autophagy)
- [Tau protein](/proteins/tau)
- [Amyloid-beta](/proteins/amyloid-beta)
References
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
[Spillantini et al., Alpha-synuclein in Lewy bodies (1997)](https://doi.org/10.1038/42166)
[Goedert et al., The synucleinopathies: Twenty years on (2017)](https://doi.org/10.1093/brain/awx056)
[Braak et al., Staging of brain pathology related to sporadic Parkinson's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12610656/)
[Jensen et al., Propagation of alpha-synuclein pathology (2019)](https://doi.org/10.1016/j.neuron.2019.04.031)
[Mak et al., Alpha-synuclein and tau pathology (2020)](https://doi.org/10.1007/s00401-020-02168-0)
[Schmitt et al., Alpha-synuclein in immune cells (2022)](https://doi.org/10.1038/s41582-022-00639-4)
[Brundin et al., Targeting alpha-synuclein for PD therapy (2023)](https://doi.org/10.1038/s41582-023-00761-9)
[Bookout et al., Alpha-synuclein and mitochondrial dysfunction (2020)](https://pubmed.ncbi.nlm.nih.gov/32976578/)
[Davie et al., A review of Parkinson's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18293108/)
[Lotharius et al., Pathogenesis and therapy of alpha-synucleinopathies (2005)](https://pubmed.ncbi.nlm.nih.gov/16033316/)
[Warner et al., Genomic cloning and chromosomal assignment of the human alpha-synuclein gene (1997)](https://pubmed.ncbi.nlm.nih.gov/9328456/)
[Li et al., Alpha-synuclein and the pathogenesis of Parkinson's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15878454/)
[Masliah et al., Dopaminergic loss and inclusion body formation in alpha-synuclein transgenic mice (2000)](https://pubmed.ncbi.nlm.nih.gov/10781069/)
[Giasson et al., A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein (2002)](https://pubmed.ncbi.nlm.nih.gov/11835695/)
[Serpell et al., Axonal dysfunction in the pathogenesis of Parkinson's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10652573/)
[Chen et al., Alpha-synuclein and autophagy in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31820756/)
[Xilouri et al., Alpha-synuclein and autophagy: A tail of two pathways (2009)](https://pubmed.ncbi.nlm.nih.gov/19158486/)
[Voutsinas et al., Protein homeostasis and aging (2010)](https://pubmed.ncbi.nlm.nih.gov/20471809/)
[Cool et al., Alpha-synuclein and the UPS in synucleinopathies (2013)](https://pubmed.ncbi.nlm.nih.gov/23684758/)
[Schapira et al., Targeting mitochondria for neuroprotection in Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23277352/)
[Lang et al., Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24896908/)
[Kalia et al., Parkinson's disease: Etiology, neuropathology, and pathogenesis (2015)](https://pubmed.ncbi.nlm.nih.gov/26746186/)
[Pokaly et al., Alpha-synuclein in Lewy body disease (2002)](https://pubmed.ncbi.nlm.nih.gov/11835463/)Cross-Linking
- [Alpha-synuclein](/proteins/alpha-synuclein)
- [SNCA](/genes/snca)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [TREM2](/proteins/trem2-protein)
- [LRRK2](/genes/lrrk2)
- [Autophagy Pathway](/mechanisms/autophagy-lysosome-pathway)
- [Neuroinflammation in Parkinson's Disease](/mechanisms/neuroinflammation-pd)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1